Viyash Scientific reported a sharp acceleration in profitability for the quarter ended June 30, 2026, with consolidated net profit after tax (PAT) surging 114.9% year-on-year to ₹793 million. The Hyderabad-based animal health and pharmaceutical company also posted a 19.5% rise in revenues to ₹9,464 million, underpinned by strong execution across its formulations, APIs, and CDMO services segments. This performance marks a significant step in the company’s post-acquisition integration journey, as it leverages scale and operational efficiency to drive margin expansion.

The filing, submitted pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, highlights a substantial improvement in operating margins. EBITDA (excluding ESOP costs) jumped 59.2% to ₹2,047 million, pushing the EBITDA margin to 21.6% from 16.2% in the corresponding quarter of FY26. The company maintained a lean balance sheet, with net debt to EBITDA standing at just 0.1x. These figures reflect the tangible benefits of the combined entity’s strategy, which focuses on disciplined execution and strategic investments in high-growth areas.

Financial Performance Overview

The consolidated financial results for Q1FY27 demonstrate broad-based growth across key metrics compared to Q1FY26.

*EBITDA refers to EBITDA excluding ESOP costs.

Strategic Drivers and Market Expansion

Dr Hari Babu Bodepudi, Managing Director and Group CEO, attributed the strong performance to the success of the company’s integration efforts and the strength of the combined entity. He highlighted that the acquisition of Bio For Life in Italy is a pivotal move in advancing Viyash’s strategic focus on the companion animal segment. This acquisition provides critical market access and a platform to launch product portfolios in key European markets, aligning with the company’s long-term growth strategy.

The management emphasized that the current quarter’s results are supported by improving operating leverage and a well-defined growth roadmap. With manufacturing, R&D, and distribution operations spanning India, Spain, Brazil, Turkey, and the USA, Viyash continues to expand its global footprint. The company serves customers in over 100 countries and holds approvals from major regulatory bodies including USFDA, EUGMP, WHO, and TGA.

What the Numbers Show

The divergence between revenue growth (19.5%) and EBITDA growth (59.2%) signals significant operating leverage being realized in the early stages of integration. The expansion of the EBITDA margin by 540 basis points to 21.6% suggests that cost synergies and higher-value mix contributions are already impacting the bottom line disproportionately to top-line growth. This margin enhancement is further validated by the net debt-to-EBITDA ratio remaining negligible at 0.1x, indicating strong cash flow generation relative to earnings.

Viyash Scientific will host an earnings call on August 12, 2026, at 3:30 PM IST, where management will discuss these results and answer questions from investors. Participants can dial +91 22 6280 1263 or +91 22 7115 8213 for the conference.

Viyash Viyash Scientific Limited (formerly Sequent Scientific Limited) will host a conference call with analysts and investors on Wednesday, August 12, 2026, at 3:30 PM IST to discuss its financial results for the quarter ended June 30, 2026. The announcement, made pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, provides stakeholders with a direct channel to review the company’s performance in Q1FY27.

The conference call aims to provide clarity on the company’s operational and financial trajectory for the initial quarter of the fiscal year. By engaging directly with market participants, management intends to address queries regarding revenue generation, cost structures, and strategic initiatives undertaken during the period. This transparency is critical for investors assessing the company’s near-term outlook and long-term growth potential in the scientific equipment and services sector.

Key leadership figures from Viyash Scientific Limited are confirmed to participate in the discussion. Dr. Hari Babu Bodepudi, Managing Director & Group CEO, will lead the session, providing overarching strategic context. He will be joined by Mr. Rajaram Narayanan, Executive Director and CEO – Animal Health, who is expected to elaborate on segment-specific performance. Mr. Ramakant Singani, Chief Financial Officer, will likely address the detailed financial metrics, cash flow dynamics, and balance sheet health presented in the quarterly filing.

Conference Call Details

Participants can access the call via the provided dial-in numbers. Early registration is facilitated through a Diamond Pass link available on the company’s investor relations portal.

The details of the conference call have been submitted to both BSE Limited and the National Stock Exchange of India Limited. The information is also publicly available on the Investors Section of the company’s website at www.viyash.com . Yoshita Vora, Company Secretary & Compliance Officer, signed the intimation letter dated August 3, 2026, ensuring regulatory compliance.

What This Means for Investors

The scheduling of this earnings call marks a standard but significant step in the corporate reporting cycle. For investors, the primary value lies in the qualitative commentary that accompanies the quantitative data. While the financial statements provide the hard numbers, the management’s narrative during the call often reveals insights into order book visibility, supply chain challenges, or shifts in customer demand that are not immediately apparent from the raw figures. Analysts will closely monitor any guidance provided for the remainder of FY27, particularly regarding margin sustainability and capital expenditure plans.